{"id":123583,"name":"HIGHMARK INC","slug":"highmark-inc","state":"PA","country":"United States of America","description":"","totalSpending":8820000,"filings":34,"yearlySpending":[{"year":2018,"income":1290000},{"year":2019,"income":1290000},{"year":2020,"income":1100000},{"year":2021,"income":1470000},{"year":2022,"income":1010000},{"year":2023,"income":980000},{"year":2024,"income":590000},{"year":2025,"income":1090000}],"issues":["TAX","HCR","MMM","BUD","PHA","GOV"],"firms":["HIGHMARK, INC."],"lobbyists":["MICHAEL WARFEL","GREGORY ENGLERT"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Centers For Medicare and Medicaid Services (CMS)","Health & Human Services, Dept of (HHS)","White House Office","Centers For Disease Control & Prevention (CDC)"],"sampleDescriptions":["Health Insurance Tax (HIT Tax); Tax Credits; Tax Reform; ACA Individual Mandate Penalty\n\nH.R.1 - An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the bu","Affordable Care Act (ACA) Regulations; Health Care Reform; Reinsurance; CSRs (Cost Sharing Reductions); Individual Mandate; Drug Pricing; Individual Market Reform; Market Stabilization; AHPs (Associat","CHIP Funding/Reform; Medicare Access & CHIP Reauthorization Act of 2015 (MACRA); Medicare Advantage; Employer Group Waiver Plans; 2019 Medicare Advantage Part D Call Letter/Rate Notice; Medicaid Provi","CSRs; Reinsurance\nH.R.1625 - Consolidated Appropriations Act of 2018\nH.R. 1892 - Bipartisan Budget Act of 2018","Drug Pricing; Opioids"],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}